<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504582</url>
  </required_header>
  <id_info>
    <org_study_id>GS01-565</org_study_id>
    <secondary_id>NCI-2012-01524</secondary_id>
    <nct_id>NCT00504582</nct_id>
  </id_info>
  <brief_title>Fibrin Melanoma Axillary Node Study in Patients With Melanoma</brief_title>
  <official_title>A Randomized Trial Evaluating the Use of Fibrin Tissue Adhesive Following Axillary Node Dissection in Patients With Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To determine whether the use of a fibrin sealant applied to axillary soft tissues&#xD;
           following node dissection can result in earlier drain removal.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To determine the postoperative morbidity rate using fibrin sealant following axillary&#xD;
           node dissection.&#xD;
&#xD;
        -  To assess patient-valuation of outcome by performing a cost-benefit analysis using a&#xD;
           willingness-to-pay model.&#xD;
&#xD;
        -  To determine if serum levels, lymphatic fluids level, or cutaneous expression of&#xD;
           vascular endothelial growth factor-D (VEGF-D), vascular endothelial growth factor-C&#xD;
           (VEGF-C) or their receptor, vascular endothelial growth factor receptor-3 (VEGFR-3)&#xD;
           correlates with nodal tumor burden or development of lymphedema in patients with&#xD;
           melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in this study are scheduled to have axillary node dissection as part of their&#xD;
      surgery for treatment of their melanoma.&#xD;
&#xD;
      Within 2 weeks before entry into the study, patients will have a complete physical exam and&#xD;
      medical history.&#xD;
&#xD;
      These patients will be randomly assigned (as in the toss of a coin) to one of two groups.&#xD;
      Patients in one group will receive TISSEEL applied externally to the dissected axillary area.&#xD;
      Patients in the other group will receive no fibrin sealant.&#xD;
&#xD;
      For patients who are admitted to the hospital, the surgical site will be monitored by the&#xD;
      surgeon for evidence of wound complications in the first 24 hours after surgery. At the time&#xD;
      of discharge from the hospital, patients will be instructed in drain care and how to measure&#xD;
      the drainage each day until the drain is removed.&#xD;
&#xD;
      The contents of the drain will be collected from patients during the first day after surgery,&#xD;
      during the first return follow-up visit to M.D. Anderson Cancer Center, and during drain&#xD;
      removal (unless these latter 2 dates are the same).&#xD;
&#xD;
      Follow-up wound exams will be performed by the local primary physician or in the M.D.&#xD;
      Anderson Melanoma Clinic between 1-4 weeks and 6 weeks after surgery. Participation will be&#xD;
      over at the 6-week follow-up.&#xD;
&#xD;
      THIS IS AN INVESTIGATIONAL STUDY. The sealant is FDA approved, though its use in this study&#xD;
      is experimental. About 115 patients will take part in this study. All will be enrolled at M.&#xD;
      D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2002</start_date>
  <completion_date type="Actual">April 9, 2020</completion_date>
  <primary_completion_date type="Actual">April 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drain Duration</measure>
    <time_frame>from surgery until drain removed, up to 40 days</time_frame>
    <description>Number of days drain was in place</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection</measure>
    <time_frame>after surgery until the wound is healed, up to 30 days whichever is longer</time_frame>
    <description>Number of participants with any signs of infection noted following surgery requiring intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Fibrin Sealant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tisseel applied externally to the dissected axillary area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Fibrin Sealant</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fibrin Sealant</intervention_name>
    <description>Tisseel applied externally to the dissected axillary area.</description>
    <arm_group_label>Fibrin Sealant</arm_group_label>
    <other_name>Tisseel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Part I - Inclusion Criteria, patients that consent to participate.&#xD;
&#xD;
          2. Patients with melanoma who have undergone axillary dissection within the last six&#xD;
             months as part of their surgical treatment will be considered for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Part II - Exclusion Criteria, patients with known hypersensitivity to bovine proteins.&#xD;
&#xD;
          2. Patient has undergone prior radiation therapy to the operative site.&#xD;
&#xD;
          3. Patient is pregnant or lactating.&#xD;
&#xD;
          4. Patient is steroid dependent within prior 6 months.&#xD;
&#xD;
          5. Patient has used aspirin or other anti-platelet drug (excluding Celebrex) within seven&#xD;
             days of operation.&#xD;
&#xD;
          6. Patient has pre-existing lymphedema.&#xD;
&#xD;
          7. Patient has other pre-existing medical conditions with evidence of organ dysfunction&#xD;
             as determined by principal investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul F. Mansfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <results_first_submitted>August 20, 2021</results_first_submitted>
  <results_first_submitted_qc>September 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2021</results_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axillary Node Dissection</keyword>
  <keyword>Fibrin Sealant</keyword>
  <keyword>Tisseel</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Seroma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 29, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT00504582/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients with the diagnosis of melanoma undergoing axillary node dissection were screened for eligibility. If they met the eligibility criteria, were offered the study. The primary outcome is to determine whether the use of a fibrin sealant applied to axillary soft tissues following node dissection can result in earlier drain removal.</recruitment_details>
      <pre_assignment_details>There were 121 total patients associated with this study. 92 patients were evaluable for the treatment study. 9 patients were inevaluable due to withdrew consent, surgery cancelled, patient elected to proceed with biopsy not surgery, not coming to MD Anderson, diagnosed with merkle cell carcinoma and sarcoma. There were 20 patients with melanoma who have undergone axillary dissection within prior six months as part of their surgical treatment who only completed the questionnaire.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Tisseel applied externally to the dissected axillary area. Intervention: Drug: Fibrin Sealant</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>No Intervention: No Fibrin Sealant</description>
        </group>
        <group group_id="P3">
          <title>Questionnaire Only</title>
          <description>Questionnaire only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics not taken for the questionnaire only arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>Tisseel applied externally to the dissected axillary area. Intervention: Drug: Fibrin Sealant</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>No Intervention: No Fibrin Sealant</description>
        </group>
        <group group_id="B3">
          <title>Questionnaire Only</title>
          <description>Questionnaire only</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline characteristics not taken for the questionnaire only arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drain Duration</title>
        <description>Number of days drain was in place</description>
        <time_frame>from surgery until drain removed, up to 40 days</time_frame>
        <population>Data not collected for Questionnaire Only Arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Tisseel applied externally to the dissected axillary area. Intervention: Drug: Fibrin Sealant</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>No Intervention: No Fibrin Sealant</description>
          </group>
          <group group_id="O3">
            <title>Questionnaire Only</title>
            <description>Questionnaire Only</description>
          </group>
        </group_list>
        <measure>
          <title>Drain Duration</title>
          <description>Number of days drain was in place</description>
          <population>Data not collected for Questionnaire Only Arm.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="7" upper_limit="40"/>
                    <measurement group_id="O2" value="21" lower_limit="5" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection</title>
        <description>Number of participants with any signs of infection noted following surgery requiring intervention.</description>
        <time_frame>after surgery until the wound is healed, up to 30 days whichever is longer</time_frame>
        <population>No data collected for Questionnaire Only Arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Tisseel applied externally to the dissected axillary area. Intervention: Drug: Fibrin Sealant</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>No Intervention: No Fibrin Sealant</description>
          </group>
          <group group_id="O3">
            <title>Questionnaire Only</title>
            <description>Questionnaire Only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection</title>
          <description>Number of participants with any signs of infection noted following surgery requiring intervention.</description>
          <population>No data collected for Questionnaire Only Arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After surgery until the wound is healed or thirty days whichever is longer.</time_frame>
      <desc>No data collected for the Questionnaire Only Arm, therefore no adverse events to report for the Questionnaire Only Arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>Tisseel applied externally to the dissected axillary area. Intervention: Drug: Fibrin Sealant</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>No Intervention: No Fibrin Sealant</description>
        </group>
        <group group_id="E3">
          <title>Questionnaire Only</title>
          <description>Questionnaire Only</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul F Mansfield, Professor, Surgical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 794-5499</phone>
      <email>pmansfie@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

